Track Niki BioSolutions's receivables ($0) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Niki BioSolutions's receivables stands at $0 as of June 2026. That compares with $14K in the prior-year period — down 100.0% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Niki BioSolutions reported $0 in receivables versus $14K a year earlier — a 100.0% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.
That compares with $14K in the prior-year period — down 100.0% year over year. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.
The history chart shows how Niki BioSolutions's receivables evolved across reporting periods, while the comparison chart places NIKI next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, receivables is commonly used to spot outliers. Niki BioSolutions's reading of $0 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.